The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.

The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.

The present disclosure provides human engineered IL-1 beta antibodies, cells and vectors comprising DNA encoding the same, and methods for producing the antibodies. In addition, the present disclosure provides the use of the human engineered IL-1 beta antibodies for the treatment of inflammatory diseases such as cardiovascular disease and cancer.

An anti-claudin antibody-drug conjugate and a pharmaceutical use thereof, specifically relating to a ligand-drug conjugate represented by general formula (Pc-L-Y-D), wherein Pc is an anti-claudin 18.2 antibody or an antigen-binding fragment thereof, and L, Y, and n are as defined in the description.

##STR00001##

The present disclosure provides anti-FGFR2b antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

An isolated monoclonal antibody that specifically binds human BCMA, or the antigen-binding portion thereof. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, or an oncolytic virus comprising the antibody or the antigen-binding portion thereof, as well as a nucleic acid molecule encoding the same.

The invention provides anti-TIM3 antibodies and methods of using the same.

Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.

The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.